temozolomide has been researched along with DIPG Brain Tumors in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Side effects associated with chemotherapy delays or modifications included thrombocytopenia (28%) and nausea/vomiting (19%), with temozolomide dosing most frequently modified." | 5.56 | Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience. ( Browd, SR; Cole, BL; Crotty, EE; Ellenbogen, RG; Ermoian, RP; Geyer, JR; Hauptman, JS; Leary, SES; Lee, A; Lockwood, CM; Millard, NE; Ojemann, JG; Olson, JM; Paulson, VA; Sato, AA; Vitanza, NA, 2020) |
| "A clinical trial using the poly (adenosine diphosphate ribose) polymerase (PARP) inhibitor veliparib concurrently with radiation therapy, followed by maintenance therapy with veliparib + temozolomide, in children with diffuse intrinsic pontine glioma was conducted by the Pediatric Brain Tumor Consortium." | 5.34 | Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. ( Baxter, P; Billups, C; Brown, D; Dunkel, IJ; Fangusaro, JR; Law, M; Onar-Thomas, A; Patay, Z; Poussaint, TY; Shiroishi, MS; Vajapeyam, S; Vezina, G, 2020) |
| " Side effects associated with chemotherapy delays or modifications included thrombocytopenia (28%) and nausea/vomiting (19%), with temozolomide dosing most frequently modified." | 1.56 | Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience. ( Browd, SR; Cole, BL; Crotty, EE; Ellenbogen, RG; Ermoian, RP; Geyer, JR; Hauptman, JS; Leary, SES; Lee, A; Lockwood, CM; Millard, NE; Ojemann, JG; Olson, JM; Paulson, VA; Sato, AA; Vitanza, NA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Izzuddeen, Y | 1 |
| Gupta, S | 1 |
| Haresh, KP | 1 |
| Sharma, D | 1 |
| Giridhar, P | 1 |
| Rath, GK | 1 |
| Vajapeyam, S | 1 |
| Brown, D | 1 |
| Billups, C | 1 |
| Patay, Z | 1 |
| Vezina, G | 1 |
| Shiroishi, MS | 1 |
| Law, M | 1 |
| Baxter, P | 1 |
| Onar-Thomas, A | 1 |
| Fangusaro, JR | 1 |
| Dunkel, IJ | 1 |
| Poussaint, TY | 1 |
| Deligne, C | 1 |
| Hachani, J | 1 |
| Duban-Deweer, S | 1 |
| Meignan, S | 1 |
| Leblond, P | 1 |
| Carcaboso, AM | 1 |
| Sano, Y | 1 |
| Shimizu, F | 1 |
| Kanda, T | 1 |
| Gosselet, F | 1 |
| Dehouck, MP | 1 |
| Mysiorek, C | 1 |
| Crotty, EE | 1 |
| Leary, SES | 1 |
| Geyer, JR | 1 |
| Olson, JM | 1 |
| Millard, NE | 1 |
| Sato, AA | 1 |
| Ermoian, RP | 1 |
| Cole, BL | 1 |
| Lockwood, CM | 1 |
| Paulson, VA | 1 |
| Browd, SR | 1 |
| Ellenbogen, RG | 1 |
| Hauptman, JS | 1 |
| Lee, A | 1 |
| Ojemann, JG | 1 |
| Vitanza, NA | 1 |
| Shi, S | 1 |
| Lu, S | 1 |
| Jing, X | 1 |
| Liao, J | 1 |
| Li, Q | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)[NCT05553041] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2023-08-07 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for temozolomide and DIPG Brain Tumors
| Article | Year |
|---|---|
The Prognostic Impact of Radiotherapy in Conjunction with Temozolomide in Diffuse Intrinsic Pontine Glioma: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Diffuse Intrinsic Pontin | 2021 |
2 trials available for temozolomide and DIPG Brain Tumors
| Article | Year |
|---|---|
Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trial.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Child | 2020 |
Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium.
Topics: Adolescent; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Benzimidazoles | 2020 |
2 other studies available for temozolomide and DIPG Brain Tumors
| Article | Year |
|---|---|
Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cells, Cultured; Diffuse Intrinsic Pont | 2020 |
Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Child | 2020 |